Medline
- Market cap
- 31.10B
- P/E (TTM)i
- 67.27
- P/Bi
- 2.69
- EPSi
- 1.43
- Div yieldi
- 0.00%
- 52W posi
- 20%
Anonymous reader poll. Unscientific, not investment advice.
Medline shares were changing hands at 35.45, down 0.28% on the day. Its market capitalisation is about 31.10B, the #667 most valuable US-listed company we track. Trading at a P/E of 65.84, the stock is 80% above its own five-year norm of 36.49. Wall Street's 20-analyst consensus lands on Buy, with a price target averaging 44.88 (+27% from here). Over the past year the stock has ranged from 31.49 to 50.88; it now sits 20% up that band.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 1 day.
- Recent price momentum is -17.6% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 4.7% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 67.9x | Better than 8% |
| Forward P/E | 20.5x | Better than 40% |
| Price / Sales | 1.0x | Better than 84% |
| P/E vs own 5-yr range | 92nd pctl | Better than 12% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 26.4% | Better than 23% |
| Operating margin | 7.8% | Better than 27% |
| Net margin | 4.1% | Better than 25% |
| Return on equity | 21.3% | Better than 70% |
| Return on invested capital | 9.5% | Better than 53% |
Momentum D
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -16.8% | Better than 15% |
| 6-month return | -17.0% | Better than 14% |
| Distance below 52-week high | 29.6% | Better than 28% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.3x | Better than 90% |
| Debt to assets | 32.8% | Better than 47% |
| Interest coverage | 2.5x | Better than 24% |
| Free cash flow / net income | 111.9% | Better than 50% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 90.0% | Better than 74% |
| Upside to average target | 25.4% | Better than 51% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 35.55
- Open
- 35.55
- Day range
- 35.21 - 35.97
- Avg price
- 35.56
- Volume
- 4.47M
- Turnover
- 159.02M
- Turnover ratei
- 1.31%
- Volume ratioi
- 0.42
- Amplitudei
- 2.14%
- 52-week rangei
- 31.49 - 50.88
Valuation
- P/Ei
- 24.84
- P/E (TTM)i
- 67.27
- P/Bi
- 2.69
- EPSi
- 1.43
- Book value / shi
- 13.19
- Net profit
- 1.25B
- Net assets
- 11.57B
Share structure
- Market cap
- 31.10B
- Float capi
- 12.09B
- Shares out
- 877.35M
- Float sharesi
- 341.00M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2025-12-17
30.3% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+103.37M net over the window
Short interest
- Shares short
- 41.31M
- % of floati
- 4.71%
- Days to coveri
- 6.43
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Medline (MDLN)?
Medline last traded at 35.45. The quote on this page refreshes every few seconds while US markets are open.
What is Medline's market cap?
About 31.10B.
What is the P/E ratio of Medline?
The trailing twelve-month P/E is 67.27, above its own 5-year average of 36.49 — toward the top of its historical range (91.71% percentile). See the Valuation tab for the full history.
Does Medline pay a dividend?
Medline does not currently pay a regular dividend.
Is Medline a buy according to analysts?
The consensus of 20 analysts is a Buy rating, with an average 12-month price target of 44.88, which implies 26.6% upside from the current price. This is not investment advice.
What is Medline's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Medline a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-08 05:19:38 · For reference only, not investment advice and not tailored to your situation.